ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0657

Artificial Intelligence-Driven Target Identification in CKD

Session Information

  • CKD Mechanisms - 2
    October 22, 2020 | Location: On-Demand
    Abstract Time: 10:00 AM - 12:00 PM

Category: CKD (Non-Dialysis)

  • 2103 CKD (Non-Dialysis): Mechanisms

Authors

  • Kumar, Chanchal, Translational Science and Experimental Medicine, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
  • Buvall, Lisa, Bioscience Renal, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
  • Ryaboshapkina, Maria, Translational Science and Experimental Medicine, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
  • Woollard, Kevin, Bioscience Renal, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
  • Williams, Julie, Bioscience Renal, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
  • Kurbatova, Natalie, Quantitative Biology, Research and Early Development, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
  • Reznichenko, Anna, Translational Science and Experimental Medicine, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
  • MacPhee, Iain, Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
  • Bohlooly, Mohammad, Translational Genomics, Research and Early Development, Discovery Biology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
  • Paul, Dirk S., Centre for Genomic Research, Research and Early Development, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
  • Dunbar, James, BenevolentAI, London, United Kingdom
  • Taddei, Andrea, BenevolentAI, London, United Kingdom
  • Davies, Mark, BenevolentAI, London, United Kingdom
  • McMahon, Siobhan, BenevolentAI, London, United Kingdom
  • Mori, Andres, BenevolentAI, London, United Kingdom
  • Fritsche-Danielson, Regina, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
  • Bendtsen, Claus, Quantitative Biology, Research and Early Development, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
  • Laerkegaard Hansen, Pernille B., Bioscience Renal, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
Background

Involvement of multiple pathways and complex pathophysiology are few of the hallmarks of Chronic Kidney Disease (CKD). These reasons contribute to the challenge for drug discovery in CKD, which is a major contributor to global disease burden. Availability of a wealth of CKD omics data has opened avenues for novel insight generation through unbiased integrative analysis. In a pioneering effort AstraZeneca and BenevolentAI initiated a collaboration to leverage the potential of artificial intelligence (AI) to generate novel hypotheses for drug targets in CKD.

Methods

We have created a CKD knowledge graph (CKD-KG) - a knowledge base of biological and chemical entities (genes, small molecules, etc) and their relationships (gene-disease associations, therapeutic drugs, biological processes, etc) and augmented with CKD specific information derived from both public and AstraZeneca proprietary data sets. The CKD-KG was constructed by aggregating information from structured biomedical databases, machine learning (ML)-based extraction from unstructured sources, and patient-centric omics datasets (i)unstructured: 140M documents, 1B relationships, (ii) structured: 30M relationships, 3B omics data points, (iii) 35 licensed data sources, and (iv) 53 CKD omics datasets. The CKD-KG was used as input to BenevolentAI’s relational inference and causal reasoning ML models to produce target hypotheses for CKD.

Results

The fleet of models identified 295 potential targets that were triaged down to 69 targets. These 69 targets have been further prioritized based on an in-house human target validation pipeline, and additional criteria such as safety and druggability, in line with AstraZeneca’s 5R framework. We are undertaking in vitro studies via genetic modification in selected cell types to generate target-specific CKD-linked readouts. Subsequently, we will employ in vivo studies to confirm the mechanism of action for targets that had shown successful in vitro readouts. Eventually, we will progress targets with compelling novel biology within our renal portfolio.

Conclusion

CKD-KG enables a transformative approach to generating novel target hypotheses with the potential of improving health outcomes for CKD patients.

Funding

  • Commercial Support